KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Nektar Therapeutics (NKTR) Equity Ratio: 2010-2025

Historic Equity Ratio for Nektar Therapeutics (NKTR) over the last 15 years, with Sep 2025 value amounting to 0.28.

  • Nektar Therapeutics' Equity Ratio rose 77.88% to 0.28 in Q3 2025 from the same period last year, while for Sep 2025 it was 0.28, marking a year-over-year increase of 77.88%. This contributed to the annual value of 0.20 for FY2024, which is 39.26% down from last year.
  • Nektar Therapeutics' Equity Ratio amounted to 0.28 in Q3 2025, which was up 342.03% from -0.12 recorded in Q2 2025.
  • Nektar Therapeutics' Equity Ratio's 5-year high stood at 0.68 during Q1 2021, with a 5-year trough of -0.12 in Q2 2025.
  • For the 3-year period, Nektar Therapeutics' Equity Ratio averaged around 0.24, with its median value being 0.28 (2025).
  • Over the last 5 years, Nektar Therapeutics' Equity Ratio had its largest YoY gain of 77.88% in 2025, and its largest YoY loss of 150.26% in 2025.
  • Nektar Therapeutics' Equity Ratio (Quarterly) stood at 0.61 in 2021, then decreased by 15.17% to 0.52 in 2022, then slumped by 36.22% to 0.33 in 2023, then crashed by 39.26% to 0.20 in 2024, then skyrocketed by 77.88% to 0.28 in 2025.
  • Its Equity Ratio stands at 0.28 for Q3 2025, versus -0.12 for Q2 2025 and 0.05 for Q1 2025.